Stock AnalizModerna, Inc. MRNA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026
Moderna, Inc. (MRNA) is a healthcare company listed in the US with a market value of about $90.4B. In the twelve months to September 30, 2026 it had revenue of $2.5B and net income of -$2.8B, a net margin of -110.5%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 19% a year, a 5-year average ROIC of 9%.
Score: 1.0 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5B | $1.9B | $3.2B | $6.8B | $19.3B | $18.5B | $803M | $60M | $135M | $206M | $108M |
| Net income | -$2.8B | -$2.8B | -$3.6B | -$4.7B | $8.4B | $12.2B | -$747M | -$514M | -$385M | -$256M | -$216M |
| Free cash flow | -$2.0B | -$2.1B | -$4.1B | -$3.8B | $4.6B | $13.3B | $2.0B | -$491M | -$437M | -$390M | $34M |
| EPS (diluted) | $-7.10 | $-7.26 | $-9.28 | $-12.33 | $20.12 | $28.29 | $-1.96 | $-1.55 | $-4.95 | $-4.18 | $-3.79 |
| Net margin | -110.5% | -145.2% | -110.0% | -68.8% | 43.4% | 66.1% | -93.0% | -856.7% | -284.8% | -124.3% | -199.5% |
| ROIC | — | -24.5% | -33.6% | -23.1% | 42.7% | 85.4% | -22.6% | -42.8% | -20.4% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 19 analysts is $158.47, 29% below the current price; targets range from $45.00 to $305.00; the consensus rating is “Hold”; expected EPS is $-7.36 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Moderna pay a dividend?
Not currently.
Is Moderna a good stock to buy?
We do not give buy or sell advice. Moderna scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.